Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabedersen and Pembrolizumab in Advanced NSCLC
NCT06579196Phase 2Active, not recruiting
- Sponsor
- University of Nebraska
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of trabedersen in non-small cell lung cancer (NSCLC), sponsored by University of Nebraska. Started May 2025; status: active, not recruiting.
02
Drugs
trabedersen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06579196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06579196.